Fig. 2

Interferon (IFN)-γ⁺ anti-human epidermal growth factor receptor 2 (HER2) CD4⁺ T cell response variations in HER2^pos patients with invasive breast cancer (IBC). IFN-γ enzyme-linked immunosorbent spot analysis of HER2 peptide-pulsed peripheral blood mononuclear cells examined anti-HER2 CD4⁺ T cell responses in patients with HER2^pos IBC, stratified by anti-HER2 responsivity, response repertoire (mean # of reactive peptides), and cumulative response (mean total SFC/10 ⁶ cells). Differences between (a) Treatment-naïve patients with HER2^pos IBC (n = 22) and those treated with trastuzumab and chemotherapy (T + C) (n = 65); and (b) patients treated with Neoadjuvant T + C (n = 40) and those treated with Adjuvant T + C (n = 25). SFC spot-forming cells